News
Asianet Newsable on MSN47m
Sarepta Pauses Shipments Of DMD Drug Elevidys Amid FDA Label Review, Stock Tumbles After-HoursH.C. Wainwright slashed its price target to $0, assigning a 'Sell' rating and saying Sarepta has no remaining intrinsic value ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback